202 related articles for article (PubMed ID: 27342914)
1. Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant.
Gordon DL; Sajkov D; Honda-Okubo Y; Wilks SH; Aban M; Barr IG; Petrovsky N
Vaccine; 2016 Jul; 34(33):3780-6. PubMed ID: 27342914
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
[TBL] [Abstract][Full Text] [Related]
3. Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine.
Honda-Okubo Y; Rajapaksha H; Sajkov D; Gordon D; Cox MMJ; Petrovsky N
Hum Vaccin Immunother; 2017 Jun; 13(6):1-11. PubMed ID: 28301280
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal.
Diallo A; Victor JC; Feser J; Ortiz JR; Kanesa-Thasan N; Ndiaye M; Diarra B; Cheikh S; Diene D; Ndiaye T; Ndiaye A; Lafond KE; Widdowson MA; Neuzil KM
Vaccine; 2018 Oct; 36(43):6424-6432. PubMed ID: 30224199
[TBL] [Abstract][Full Text] [Related]
5. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
[TBL] [Abstract][Full Text] [Related]
6. Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection.
Honda-Okubo Y; Ong CH; Petrovsky N
Vaccine; 2015 Sep; 33(38):4892-900. PubMed ID: 26232344
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.
Gordon D; Kelley P; Heinzel S; Cooper P; Petrovsky N
Vaccine; 2014 Nov; 32(48):6469-77. PubMed ID: 25267153
[TBL] [Abstract][Full Text] [Related]
8. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
Vaccine; 2022 Feb; 40(9):1271-1281. PubMed ID: 35125219
[TBL] [Abstract][Full Text] [Related]
10. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant.
Gordon DL; Sajkov D; Woodman RJ; Honda-Okubo Y; Cox MM; Heinzel S; Petrovsky N
Vaccine; 2012 Aug; 30(36):5407-16. PubMed ID: 22717330
[TBL] [Abstract][Full Text] [Related]
11. A Multi-Season Randomised Controlled Trial of Advax-Adjuvanted Seasonal Influenza Vaccine in Participants with Chronic Disease or Older Age.
Sajkov D; Woodman R; Honda-Okubo Y; Barbara J; Chew D; Toson B; Petrovsky N
J Infect Dis; 2023 Dec; ():. PubMed ID: 38157402
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
[TBL] [Abstract][Full Text] [Related]
13. Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.
Feldstein LR; Matrajt L; Elizabeth Halloran M; Keitel WA; Longini IM;
Vaccine; 2016 Jul; 34(33):3796-802. PubMed ID: 27268778
[TBL] [Abstract][Full Text] [Related]
14. A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection.
Honda-Okubo Y; Kolpe A; Li L; Petrovsky N
Vaccine; 2014 Aug; 32(36):4651-9. PubMed ID: 24958701
[TBL] [Abstract][Full Text] [Related]
15. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.
Honda-Okubo Y; Saade F; Petrovsky N
Vaccine; 2012 Aug; 30(36):5373-81. PubMed ID: 22728225
[TBL] [Abstract][Full Text] [Related]
16. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
van de Witte S; Nauta J; Montomoli E; Weckx J
Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
Frey SE; Reyes MR; Reynales H; Bermal NN; Nicolay U; Narasimhan V; Forleo-Neto E; Arora AK
Vaccine; 2014 Sep; 32(39):5027-34. PubMed ID: 25045825
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
19. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.
Wong TM; Petrovsky N; Bissel SJ; Wiley CA; Ross TM
Hum Vaccin Immunother; 2016 Aug; 12(8):2096-2105. PubMed ID: 27215855
[TBL] [Abstract][Full Text] [Related]
20. Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge.
Tomar J; Patil HP; Bracho G; Tonnis WF; Frijlink HW; Petrovsky N; Vanbever R; Huckriede A; Hinrichs WLJ
J Control Release; 2018 Oct; 288():199-211. PubMed ID: 30218687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
